Pharmacological properties : תכונות פרמקולוגיות

Pharmacodynamic Properties

5.1 Pharmacodynamic properties
Pharmacotherapeutic group:
Virustatic agent and antiparkinsonian agent
ATC code: N04BB01

Amantadine has many pharmacological effects. Amantadine has an indirect agonistic effect on the striatal dopamine receptor. Animal studies have shown that Amantadine increases the extracellular dopamine concentration by increasing dopamine release, as well as by inhibiting reuptake in presynaptic neurons. Amantadine inhibits NMDA receptor-mediated release of acetylcholine at therapeutic levels and may induce anticholinergic effects.. With L-Dopa it shows synergistic effects.
Amantadine inhibits the proton pump activity of the influenza A matrix protein 2 (M2). This inhibits the release of the nucleic acids of already invading viruses and thus the uptake of the viral ribonucleic complex in the cell nucleus of the target cell, as well as blocking the release of infectious particles from infected cells.
The protection rate prior to infection varies between 50 and 95%. Amantadine may reduce the duration and severity of the disease by 50%, if therapy is started in a timely manner..
Under therapy with amantadine, stable mutations leading to resistant phenotypes are selected.
After 5-7 days, 50% of all isolates are resistant. Resistant strains can be transmitted from person to person.

Pharmacokinetic Properties